Demographic, clinical, and laboratory features at baseline in the SPRINT trial
| Variable∗ . | Low-dose group (n = 49) . | Moderate-dose group (n = 52) . | P† . |
|---|---|---|---|
| Age at enrollment, y | 6.0 (4.1-8.0) | 6.6 (4.2-9.1) | .392 |
| Female sex | 23 (46.9) | 22 (42.3) | .640 |
| Follow-up time, y | 1.9 (1.1-2.4) | 1.5 (1.0-2.3) | .281 |
| Height, cm | 111.4 (98.3-120.6) | 112.2 (98.8-122.9) | .704 |
| Weight, kg | 16.0 (13.2-18.4) | 15.4 (12.1-19.0) | .868 |
| Body mass index, kg/m2 | 13.2 (12.1-14.1) | 13.0 (12.3-14.4) | .796 |
| Total Hb, g/dL | 7.9 (7.2-8.8) | 8.0 (6.9-8.6) | .403 |
| HbF (n = 100), % | 8.2 (4.4-15.8) | 7.7 (4.1-11.3) | .296 |
| White blood cell count, ×109/L | 14.4 (10.2-19.2) | 13.2 (10.2-17.6) | .497 |
| Platelets, ×103/μL | 469.0 (302.0-616.5) | 424.0 (351.2-536.8) | .439 |
| ANC per μL | 6594.0 (4593.2-9133.4) | 5790.7 (4429.6-8930.0) | .644 |
| Systolic blood pressure, mm Hg | 90.0 (80.0-95.0) | 90.0 (80.0-97.2) | .725 |
| MCV, fL | 84.0 (76.6-93.4) | 82.8 (77.0-87.9) | .331 |
| Variable∗ . | Low-dose group (n = 49) . | Moderate-dose group (n = 52) . | P† . |
|---|---|---|---|
| Age at enrollment, y | 6.0 (4.1-8.0) | 6.6 (4.2-9.1) | .392 |
| Female sex | 23 (46.9) | 22 (42.3) | .640 |
| Follow-up time, y | 1.9 (1.1-2.4) | 1.5 (1.0-2.3) | .281 |
| Height, cm | 111.4 (98.3-120.6) | 112.2 (98.8-122.9) | .704 |
| Weight, kg | 16.0 (13.2-18.4) | 15.4 (12.1-19.0) | .868 |
| Body mass index, kg/m2 | 13.2 (12.1-14.1) | 13.0 (12.3-14.4) | .796 |
| Total Hb, g/dL | 7.9 (7.2-8.8) | 8.0 (6.9-8.6) | .403 |
| HbF (n = 100), % | 8.2 (4.4-15.8) | 7.7 (4.1-11.3) | .296 |
| White blood cell count, ×109/L | 14.4 (10.2-19.2) | 13.2 (10.2-17.6) | .497 |
| Platelets, ×103/μL | 469.0 (302.0-616.5) | 424.0 (351.2-536.8) | .439 |
| ANC per μL | 6594.0 (4593.2-9133.4) | 5790.7 (4429.6-8930.0) | .644 |
| Systolic blood pressure, mm Hg | 90.0 (80.0-95.0) | 90.0 (80.0-97.2) | .725 |
| MCV, fL | 84.0 (76.6-93.4) | 82.8 (77.0-87.9) | .331 |
Based on the intention-to-treat analysis, participants with SCA with a previous stroke were randomly allocated to receive fixed low- (∼10 mg/kg per day) or moderate-dose (∼20 mg/kg per day) hydroxyurea and were followed for a median of 1.6 years (IQR, 1.0-2.3).
MCV, mean cell volume.
Count (percent) for categorical variables median (IQR) for continuous variables.
χ2 test for categorical variables; Mann-Whitney test for continuous variables.